Skip to main content

Table 1 FDA approved drugs in clinical trials for COVID-19 treatment

From: Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2

Zidovudine

Linagliptin

Chlorpromazine

Bevacizumab

Sofosbuvir

Hydroxychloroquine

Telmisartan

Lenalidomide

Tinzaparin

Vitamina

Lopinavir

Anakinra

Methotrexate

Naproxen

Metformin

Tocilizumab

Vitaminc

Tirofiban

Ritonavir

Berberine

Sarilumab

Zinc

Clopidogrel

Tacrolimus

Licorice

Atazanavir

Almitrine

Acetylsalicylicacid

Celecoxib

Bromhexine

Tranexamicacid

Sitagliptin

Fondaparinux

Tofacitinib

Minocycline

Alteplase

Ciclesonide

Ramipril

Pirfenidone

Lithium

Canakinumab

Acalabrutinib

Progesterone

Hydrogenperoxide

Formoterol

Ruxolitinib

Etoposide

Captopril

Sildenafil

Indomethacin

Colchicine

Ketamine

Eculizumab

Ixekizumab

Selenium

Leflunomide

Losartan

Sevoflurane

Dexmedetomidine

Nintedanib

Oxygen

Valsartan

Nitazoxanide

Lipoicacid

Spironolactone

Sirolimus

Baricitinib

Sargramostim

Tranilast

Imatinib

Povidone-iodine

Fluoxetine

Ribavirin

Adalimumab

Estradiol

Fluvoxamine

Vitamind

Nivolumab

Thalidomide

Chloroquine

Ibuprofen

Bicalutamide

Melatonin

Fingolimod

Azithromycin

Aviptadil

Ivermectin

Simvastatin

Suramin

Dexamethasone

Doxycycline

Sodiumbicarbonate

Dapagliflozin

Itraconazole

Oseltamivir

Enoxaparin

Ibrutinib

Amiodarone

Mefloquine

Amoxicillin

Prazosin

Levamisole

Verapamil

Dalteparin

Clavulanate

Isotretinoin

Deferoxamine

Siltuximab

Nadroparin

Darunavir

Heparin

Methyleneblue

Defibrotide

Iloprost

Â